Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma By Ogkologos - May 14, 2026 143 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Cancer Research UK’s Race for Life celebrates its 30th year by... April 24, 2023 Courageous children receive Star Awards in virtual celebration December 17, 2021 New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer July 2, 2026 FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer June 27, 2025 Load more HOT NEWS Consensus on Conceptual Framework for Precision Cancer Medicine in Germany ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ Avapritinib Not Superior to Regorafenib in Terms of Median PFS in... Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with...
